Literature DB >> 11353648

Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria.

N Kleinkauf1, G Ackermann, R Schaumann, A C Rodloff.   

Abstract

The in vitro activity of gemifloxacin was compared to that of other quinolone and nonquinolone antimicrobials against 204 anaerobes by the agar dilution technique. The data indicate that gemifloxacin has a rather selective anaerobic activity. Most Peptostreptococcus, Porphyromonas, and Fusobacterium species are susceptible, while gemifloxacin's activity against other gram-negative anaerobes appears to be variable.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353648      PMCID: PMC90568          DOI: 10.1128/AAC.45.6.1896-1899.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.

Authors:  E J Goldstein
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

2.  Comparative in vitro activity of gemifloxacin.

Authors:  A King; J May; G French; I Phillips
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

3.  Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.

Authors:  J Dubois; C St-Pierre
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

4.  Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria.

Authors:  F Marco; M S Barrett; R N Jones
Journal:  J Antimicrob Chemother       Date:  1997-10       Impact factor: 5.790

5.  Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes.

Authors:  E J Goldstein; D M Citron; C Vreni Merriam; K Tyrrell; Y Warren
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

6.  In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.

Authors:  E J Goldstein; D M Citron; M Hudspeth; S Hunt Gerardo; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

7.  The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.

Authors:  R Wise; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

8.  Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.

Authors:  M G Cormican; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

9.  In vitro activity of gemifloxacin (SB 265805) against anaerobes.

Authors:  E J Goldstein; D M Citron; Y Warren; K Tyrrell; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

10.  Characterization of indole-negative Bacteroides fragilis group species with use of polymerase chain reaction fingerprinting and resistance profiles.

Authors:  M C Claros; D M Citron; S Hunt Gerardo; E J Goldstein; G Schönian; T Montag; B Hampel; A C Rodloff
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

View more
  5 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Genetic determinant of intrinsic quinolone resistance in Fusobacterium canifelinum.

Authors:  Georg Conrads; Diane M Citron; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study.

Authors:  B Al-Nawas; C Walter; T Morbach; N Seitner; E Siegel; M Maeurer; F Krummenauer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-29       Impact factor: 3.267

5.  Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.

Authors:  Gary E Stein; Sharon Schooley; Kerin L Tyrrell; Diane M Citron; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.